#### Edgar Filing: CYTOKINETICS INC - Form 4

CYTOKINET Form 4 April 17, 2006									
FORM	Л						OMB A	PPROVAL	
	TATES	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549				OMB Number:	3235-0287		
Check this if no longe subject to Section 16	STATEM	x STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Section 16. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type Re	esponses)								
1. Name and Address of Reporting Person <u>*</u> TRAUTMAN JAY K			2. Issuer Name <b>and</b> Ticker or Trading Symbol CYTOKINETICS INC [CYTK]			5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (M	iddle)		Earliest Tra		(Check all applicable)			
(Last) (First) (Middle) 280 EAST GRAND AVENUE (Street)			(Month/Da 04/17/20	ay/Year)	msaction	Director       10% Owner         Officer (give title       Other (specify below)         below)       below)         VP, Disc Biology & Technology			
			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
SOUTH SAN FRANCISCO						Form filed by M Person	ore than One Re	eporting	
(City)	(State) (Z	Zip)	Table	e I - Non-Do	erivative Securities Ac	quired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any	ned	3.	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	

 $\begin{array}{cccc}
 & (A) &$ 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

D

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactie Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		tion Date		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha	
Incentive Stock Option (right to buy)	\$ 1.2					07/10/2002(2)	07/10/2012	Common Stock	17,5	
Incentive Stock Option (right to buy)	\$ 1.2					05/21/2003 <u>(3)</u>	05/21/2013	Common Stock	12,5	
Incentive Stock Option (right to buy)	\$ 6.5					04/08/2004(4)	03/08/2014	Common Stock	25,0	
Incentive Stock Option (right to buy)	\$ 6.59					04/11/2005(5)	04/11/2015	Common Stock	30,0	
Incentive Stock Option (right to buy)	\$ 6.88					01/07/2006(6)	12/15/2015	Common Stock	21,50	
Incentive Stock Option (right to buy)	\$ 7.15					03/01/2006(7)	03/01/2016	Common Stock	2,50	
Non-Qualified Stock Option (right to buy)	\$ 6.88					01/07/2006(6)	12/15/2015	Common Stock	43,49	
Non-Qualified Stock Option (right to buy)	\$ 7.15					03/01/2006(7)	03/01/2016	Common Stock	37,5	

### Edgar Filing: CYTOKINETICS INC - Form 4

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationsnips					
	Director	10% Owner	Officer	Other		
TRAUTMAN JAY K			VP, Disc			
280 EAST GRAND AVENUE			Biology &			
SOUTH SAN FRANCISCO, CA 94080			Technology			

# Signatures

By: Sharon Surrey-Barbari For: Jay K. Trautman, PhD.

\*\*Signature of Reporting Person

04/17/2006 Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2005.
- (2) This option is immediately exercisable upon grant and shall vest as to 15,625 shares on 06/03/03 and the balance of 46,875 divided into equal monthly installments thereafter such that the option shall be 100% vested on 06/03/06.
- (3) This option is immediately exercisable upon grant and shall vest as to 573 shares on 04/01/03 and the balance of 26,927 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/07.
- (4) This option shall vest and become exercisable as to 521 shares on 04/08/04 and the balance of 24,479 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/08/08.
- (5) This option shall vest and become exercisable as to 30,000 shares divided into equal monthly installments such that the option shall be 100% vested on 03/01/2009.
- (6) When the ISO and NQ dated 12/15/05 are combined for a total grant of 65,000 shares, the option shall vest and become exercisable as to 65,000 shares divided into equal monthly installments such that the option shall be 100% vested on 12/07/2009.
- (7) When the ISO and NQ dated 03/01/2006 are combined for a total grant of 40,000 shares, the option shall vest and become exercisable as to 40,000 shares divided into equal monthly installments such that the option shall be 100% vested on 03/01/2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.